The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.
Standard
The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer. / Saad, Fred; Pantel, Klaus.
in: FUTURE ONCOL, Jahrgang 8, Nr. 3, 3, 2012, S. 321-331.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.
AU - Saad, Fred
AU - Pantel, Klaus
PY - 2012
Y1 - 2012
N2 - Prostate-specific antigen (PSA) has been used for over two decades as a serum marker for adenocarcinoma of the prostate. Although PSA screening remains an important part of disease screening and monitoring in early prostate cancer (PC), its utility in monitoring disease progression in advanced PC is undetermined. Furthermore, the role of PSA monitoring in the management of patients with PC and bone metastases appears limited. The purpose of this review is to evaluate the role of circulating tumor cells (CTCs) as potential novel biomarkers in advanced PC. We present a review of CTC testing and the clinical data supporting the prognostic potential of CTCs in this setting. We propose that combination of CTCs and PSA velocity or doubling-time assessments may offer insights into the prognosis and management of advanced PC.
AB - Prostate-specific antigen (PSA) has been used for over two decades as a serum marker for adenocarcinoma of the prostate. Although PSA screening remains an important part of disease screening and monitoring in early prostate cancer (PC), its utility in monitoring disease progression in advanced PC is undetermined. Furthermore, the role of PSA monitoring in the management of patients with PC and bone metastases appears limited. The purpose of this review is to evaluate the role of circulating tumor cells (CTCs) as potential novel biomarkers in advanced PC. We present a review of CTC testing and the clinical data supporting the prognostic potential of CTCs in this setting. We propose that combination of CTCs and PSA velocity or doubling-time assessments may offer insights into the prognosis and management of advanced PC.
KW - Humans
KW - Male
KW - Prognosis
KW - Disease Progression
KW - Neoplastic Cells, Circulating/pathology
KW - Prostate-Specific Antigen/blood
KW - Tumor Markers, Biological/blood
KW - Prostate/pathology
KW - Bone Neoplasms/diagnosis/secondary/therapy
KW - Prostatic Neoplasms/diagnosis/pathology/therapy
KW - Humans
KW - Male
KW - Prognosis
KW - Disease Progression
KW - Neoplastic Cells, Circulating/pathology
KW - Prostate-Specific Antigen/blood
KW - Tumor Markers, Biological/blood
KW - Prostate/pathology
KW - Bone Neoplasms/diagnosis/secondary/therapy
KW - Prostatic Neoplasms/diagnosis/pathology/therapy
M3 - SCORING: Journal article
VL - 8
SP - 321
EP - 331
JO - FUTURE ONCOL
JF - FUTURE ONCOL
SN - 1479-6694
IS - 3
M1 - 3
ER -
